Human Mutation · 2012 · 127 citations · 24 references
Life SciencesGeneticsMolecular GeneticsCardiovascular GeneticsGenomicsMedical GeneticsFamilial HypercholesterolemiaGenetic DisordersLipid Disorder GeneticsLipid DisordersLipid Metabolism DisordersApoe GeneticsApolipoprotein E VariantsAutosomal Dominant InheritanceExome SequencingFamilial Combined HyperlipidemiaPcsk9 Gain-of-function MutationsWhole Exome Sequencing StudiesWhole-exome Sequencing Analysis
Apolipoprotein (apo) E mutants are associated with type III hyperlipoproteinemia characterized by high cholesterol and triglycerides levels. Autosomal dominant hypercholesterolemia (ADH), due to the mutations in the LDLR, APOB, or PCSK9 genes, is characterized by an isolated elevation of cholesterol due to the high levels of low-density lipoproteins (LDLs). We now report an exceptionally large family including 14 members with ADH. Through genome-wide mapping, analysis of regional/functional candidate genes, and whole exome sequencing, we identified a mutation in the APOE gene, c.500_502delTCC/p.Leu167del, previously reported associated with sea-blue histiocytosis and familial combined hyperlipidemia. We confirmed the involvement of the APOE p.Leu167del in ADH, with (1) a predicted destabilization of an alpha-helix in the binding domain, (2) a decreased apo E level in LDLs, and (3) a decreased catabolism of LDLs. Our results show that mutations in the APOE gene can be associated with bona fide ADH.
24
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Marianne Abifadel, Mathilde Varret, Jean‐Pierre Rabès et al. · Nature Genetics · 2003 · 3K citations
The Metabolic Basis of Inherited Diseases
R.K. Winkelmann · Archives of Dermatology · 1972 · 1.8K citations
Gérard Siest, Sophie Visvikis‐Siest, Bernard Herbeth et al. · Clinical Chemistry and Laboratory Medicine (CCLM) · 1998 · 137 citations
Medicine, Cardiology, Genetics +16